SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-19-314351
Filing Date
2019-12-16
Accepted
2019-12-16 06:51:10
Documents
12
Period of Report
2019-12-10
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d846918d8k.htm   iXBRL 8-K 41657
  Complete submission text file 0001193125-19-314351.txt   169259

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA bold-20191210.xsd EX-101.SCH 3077
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE bold-20191210_lab.xml EX-101.LAB 18140
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE bold-20191210_pre.xml EX-101.PRE 11413
13 EXTRACTED XBRL INSTANCE DOCUMENT d846918d8k_htm.xml XML 3372
Mailing Address 600 CALIFORNIA ST., 17TH FLOOR SAN FRANCISCO CA 94108
Business Address 600 CALIFORNIA ST., 17TH FLOOR SAN FRANCISCO CA 94108 415-638-6556
Audentes Therapeutics, Inc. (Filer) CIK: 0001628738 (see all company filings)

IRS No.: 461606174 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37833 | Film No.: 191285835
SIC: 2836 Biological Products, (No Diagnostic Substances)